After a decade of scant gains, some investors are now piling into pharmaceuticals as a combination of high yields and attractive valuations draw managers in, but is this the start of a decade-long move up?
Even in the context of their status as perennial cautious plays, drug companies have produced little in the way of capital growth over the past decade, particularly compared with some defensive peers....
Latest news and analysis
New green finance standards also unveiled
Previously head of ETF & indexing sales
Letter to Women and Equalities Committee